Neurodegenerative Disease Market
完整報告名稱與涵蓋範圍
Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Drug Class (NMDA, SSRIs, Decarboxylase inhibitors, Cholinesterase Inhibitors, Immunomodulators, Dopamine Inhibitors), By Applications, Region And Segment Forecasts, 2025-2034.
報告摘要
A CAGR of 5.0% is forecasted for the global Neurodegenerative Disease Market over the assessment period of 2025 through 2034.
At its core, Neurodegenerative Disease pertains to landscape are escalatingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened appetite for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and escalating investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neurodegenerative Disease Market Snapshot
Chapter 4. Global Neurodegenerative Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. By Drug Class & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Class:
5.2.1. NMDA
5.2.2. SSRIs
5.2.3. Decarboxylase inhibitors
5.2.4. Cholinesterase Inhibitors
5.2.5. Immunomodulators
5.2.6. Dopamine Inhibitors
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. By Application & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
6.2.1. Parkinson's Disease
6.2.2. Huntington Disease
6.2.3. Amyotrophic Lateral Sclerosis
6.2.4. Alzheimer's Disease
Chapter 7. Neurodegenerative Disease Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts By Drug Class, 2021 - 2034
7.1.2. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts By Application, 2021 - 2034
7.1.3. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts by country, 2021 - 2034
7.2. Europe
7.2.1. Europe Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, 2021 - 2034
7.2.2. Europe Neurodegenerative Disease Market revenue (US$ Million) By Application, 2021 - 2034
7.2.3. Europe Neurodegenerative Disease Market revenue (US$ Million) by country, 2021 - 2034
7.3. Asia Pacific
7.3.1. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, 2021 - 2034
7.3.2. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) By Application, 2021 - 2034
7.3.3. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) by country, 2021 - 2034
7.4. Latin America
7.4.1. Latin America Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, (US$ Million)
7.4.2. Latin America Neurodegenerative Disease Market revenue (US$ Million) By Application, (US$ Million)
7.4.3. Latin America Neurodegenerative Disease Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, (US$ Million)
7.5.2. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) By Application, (US$ Million)
7.5.3. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Novartis
8.2.2. Pfizer
8.2.3. Merck Serono
8.2.4. Biogen Idec
8.2.5. TEVA
8.2.6. UCB
8.2.7. Boehringer Ingelheim
8.2.8. Sanofi
8.2.9. GlaxoSmithKline
8.2.10. Other Key Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們